Skip to main navigation Skip to search Skip to main content

Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma

  • M. F. Roesdi*
  • , T. J. Postma
  • , O. S. Hoekstra
  • , C. J. Van Groeningen
  • , J. G. Wolbers
  • , J. J. Heimans
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Combination chemotherapy with procarbazine, CCNU and vincristine (PCV) may be effective in patients with recurrent glioma. Response monitoring is mandatory, but radiological response evaluation is often difficult. We evaluated Thallium-201 (201Tl) SPECT as a response parameter in ten patients treated with intensive PCV chemotherapy for recurrent glioma. 201Tl-SPECT studies showed early changes (decreasing volume and intensity) in nine patients and these changes were more pronounced than radiological findings. 201Tl-SPECT results after completion of chemotherapy seemed to correlate with clininal findings during follow up. We conclude that 201Tl-SPECT may contribute to the assessment of response in patients treated with PCV chemotherapy for recurrent glioma.

Original languageEnglish
Pages (from-to)251-255
Number of pages5
JournalJournal of neuro-oncology
Volume40
Issue number3
DOIs
Publication statusPublished - 1998

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Chemotherapy
  • Recurrent glioma
  • Response parameter
  • Thallium-201 SPECT

Fingerprint

Dive into the research topics of 'Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma'. Together they form a unique fingerprint.

Cite this